{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:40:30Z","timestamp":1789206030003,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ygyno.2017.06.001","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T19:16:51Z","timestamp":1496949411000},"page":"299-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure"],"prefix":"10.1016","volume":"146","author":[{"given":"Samuel","family":"Lurie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossi","family":"Mizrachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabi","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Schejter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.06.001_bb0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00430-003-0181-2","article-title":"Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts","volume":"193","author":"Gross","year":"2004","journal-title":"Med. Microbiol. Immunol."},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2017.06.001_bb0010","article-title":"Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease","volume":"24","author":"Lacey","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2017.06.001_bb0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/11594780-000000000-00000","article-title":"Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel: accounting for CIN1 and genital warts in addition to CIN2\/3 and cervical cancer","volume":"10","author":"Shavit","year":"2012","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.ygyno.2017.06.001_bb0020","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0025","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"FUTURE I\/II Study Group","year":"2010","journal-title":"BMJ"},{"issue":"2016","key":"10.1016\/j.ygyno.2017.06.001_bb0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2174\/1574887111666160502160748","article-title":"Development of human papillomavirus (HPV) vaccines: a review of literature and clinical update","volume":"11","author":"Sangar","year":"2016","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.ygyno.2017.06.001_bb0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0040","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jnci\/djt032","article-title":"Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study","volume":"105","author":"Leval","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2013.12.005","article-title":"The Australian experience with the human papillomavirus vaccine","volume":"36","author":"Garland","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0050","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2340\/00015555-1721","article-title":"A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women--an ecological study","volume":"94","author":"Sand\u00f8","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0055","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/OLQ.0000000000000369","article-title":"Trends in male and female genital warts among adolescents in a safety-net health care system 2004\u20132013: correlation with introduction of female and male human hapillomavirus vaccination","volume":"42","author":"Perkins","year":"2015","journal-title":"Sex. Transm. Dis."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132404","article-title":"Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study","volume":"10","author":"Dominiak-Felden","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2017.06.001_bb0065","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S0950268815002198","article-title":"Prophylactic HPV vaccination: past, present, and future","volume":"144","author":"Castle","year":"2016","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0070","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 8","key":"10.1016\/j.ygyno.2017.06.001_bb0075","doi-asserted-by":"crossref","first-page":"I42","DOI":"10.1016\/j.vaccine.2012.06.099","article-title":"Cervical cancer screening, human papillomavirus vaccination practices and current infrastructure in Israel","volume":"31","author":"Schejter","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2017.06.001_bb0080","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1016\/j.vaccine.2007.07.018","article-title":"Cost-utility analysis of vaccination against HPV in Israel","volume":"25","author":"Ginsberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2017.06.001_bb0085","first-page":"1","article-title":"Natural history of genital warts","volume":"47","author":"Oriel","year":"1971","journal-title":"Br. J. Vener. Dis."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0090","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex. Transm. Infect."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2334-13-39","article-title":"Systematic review of the incidence and prevalence of genital warts","volume":"13","author":"Patel","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0100","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2017.06.001_bb0105","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/jir285","article-title":"Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity","volume":"204","author":"Brisson","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"127 Suppl","key":"10.1016\/j.ygyno.2017.06.001_bb0110","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1097\/01.AOG.0000483628.84944.92","article-title":"HPV vaccination does not provide herd immunity for unvaccinated women or cross-protection for nonvaccine HPV types [12]","volume":"1","author":"Tarney","year":"2016","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.06.001_bb0115","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect. Dis."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730896X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730896X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T01:50:30Z","timestamp":1535766630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581730896X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S009082581730896X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.06.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}